Elicio Therapeutics, Inc.
ELTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.70
KIRA · Stoqly’s AI analyst, in plain words
- Elicio Therapeutics, Inc. lost $39.6M in fiscal 2025.
- Free cash flow was −$37.0M in fiscal 2025, — of revenue.
- Elicio Therapeutics, Inc. has $8.6M more cash than debt.
Market cap
$32.7M
P/E
—
Revenue
—
Net income
−$39.6M
Free cash flow
−$37.0M
Operating margin
—
Elicio Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$39.6M
No. It lost money last year.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Elicio Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Elicio Therapeutics, Inc.
- CIK
- 0001601485
Elicio Therapeutics, Inc. · ELTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $28.3M | $2.3M | — | — | — |
| Revenue growth | 883.1% | −91.9% | — | — | — |
| Net interest income | −$1.8M | $0.8M | — | — | — |
| Gross margin | 98.5% | 100.0% | — | — | — |
| Operating margin | −138.8% | −1,031.4% | — | — | — |
| Net income | −$54.6M | −$28.2M | −$35.2M | −$51.9M | −$39.6M |
| Net margin | −192.8% | −1,225.9% | — | — | — |
| Diluted EPS | −$1.93 | −$89.27 | −$6.96 | −$4.25 | −$2.58 |
| Cash | |||||
| Cash from operations | −$52.6M | −$22.2M | −$32.7M | −$37.1M | −$37.0M |
| Capital expenditure | $0.4M | $0.7M | $0.1M | $0.1M | $0.0M |
| Free cash flow | −$53.0M | −$22.8M | −$32.8M | −$37.2M | −$37.0M |
| FCF margin | −187.3% | −992.3% | — | — | — |
| Share count change | 91.3% | −98.9% | 1,500.1% | 141.3% | 25.5% |
| Debt and strength | |||||
| Cash and short-term investments | $88.8M | $6.2M | $12.9M | $17.6M | $18.6M |
| Debt incl. finance leases | $0.3M | — | — | $20.0M | $10.0M |
| Shareholders' equity | −$74.5M | −$102M | $11.4M | −$11.3M | $1.6M |
| Current ratio | 8.1x | 1.6x | 1.7x | 1.8x | 2.4x |
| Interest coverage | — | −6.6x | −33.8x | −98.9x | −33.3x |
| Returns and quality | |||||
| Return on equity | — | — | — | −170,157.4% | — |
| Return on tangible equity | — | — | −309.5% | — | −2,418.8% |
| Piotroski F-score | 6 | 3 | — | — | 4 |
| Altman Z'' | −9.8 | −29.1 | −23.6 | −31.4 | −36.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Elicio Therapeutics, Inc. · ELTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.70 a share, the company is worth $32.7M.
Source: SEC EDGAR XBRL filings (CIK 0001601485). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.